Binata Marik*

Departments of Anatomy and Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India

*Corresponding Author: Binata Marik, Departments of Anatomy and Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Received: August 02, 2022; Published: September 01, 2022

Abstract

Hemolytic anaemia, thrombocytopenia, and acute renal failure are the three components of hemolytic-uremic syndrome (HUS). Shiga toxin produced by E. coli is the main culprit (STEC HUS). The absence of STEC infection distinguishes atypical HUS (aHUS) from conventional HUS. A normal level of ADAMTS13 can also help distinguish it from thrombotic thrombocytopenic purpura (TTP). Atypical HUS can appear at any age, from infancy to adulthood. The cases with hereditary origins make for about 60% of aHUS. Even after full treatment, these people frequently experience relapse. In about 60% of these instances, end-stage renal failure develops (ESRD).

References

1. Goodship TH., et al. “Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "kidney disease: Improving Global Outcomes" (KDIGO) Controversies Conference”. Kidney International 91 (2017): 539-551.
2. Esparza-Gordillo J., et al. “Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree”. Molecular Immunology 43 (2006): 1769-1775.
3. Zipfel PF., et al. “CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy”. Journal of the American Society of Nephrology 31 (2020): 241-256.
4. Fakhouri F and Frémeaux-Bacchi V. “Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics”. Nature Reviews Nephrology 17 (2021): 543-553.
5. Funato M., et al. “A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome”. Journal of Clinical Immunology 34 (2014): 691-695.
6. Richards A., et al. “Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome”. Proceedings of the National Academy of Sciences of the United States of America 100 (2003): 12966-12971.
7. Caprioli J., et al. “Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome”. Blood 108 (2006): 1267-1279.
8. Noris M and Remuzzi G. “Thrombotic microangiopathy after kidney transplantation”. American Journal of Transplantation 10 (2010): 1517-1523.
9. Landau D., et al. “Familial hemolytic uremic syndrome associated with complement factor H deficiency”. The Journal of Pediatrics 138 (2001): 412-417.
10. Lemaire M., et al. “Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome”. Nature Genetics 45 (2013): 531-536.

Citation

Citation: Binata Marik. “Importance of Genetic Testing in the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome". Acta Scientific Paediatrics 5.10 (2022): 01-03.

Copyright

Copyright: © 2022 Binata Marik. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.